CYP1A2 and Parkinson disease: One case–control study in a Japanese cohort found decreased serum caffeine in a population of moderate-advanced PD patients as compared to healthy subjects (HS), with no differences in CYP1A2 genotype, which is the enzyme responsible for 95% of caffeine metabolism to paraxanthine, or caffeine intake 5.